Examining Changes in Clinical Management and Postpartum Readmissions for Hypertensive Disorders of Pregnancy over Time

• Published in: Pregnancy hypertension Vol. 30; pp. 82 - 86
• Main Authors: Kumar, Natasha R., Eucalitto, Patrick F., Trawick, Emma, Lancki, Nicola, Yee, Lynn M.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.12.2022
• Subjects: antenatal management; Female; gestational hypertension; Humans; Hypertension, Pregnancy-Induced - diagnosis; Hypertension, Pregnancy-Induced - drug therapy; hypertensive disorders of pregnancy; Magnesium - therapeutic use; Patient Readmission; Postpartum Period; Postpartum readmission; Pre-Eclampsia; preeclampsia; Pregnancy; Retrospective Studies; gestational hypertension; PPR; HDP; Postpartum readmission; hypertensive disorders of pregnancy; preeclampsia; antenatal management; Antenatal management; Gestational hypertension; Preeclampsia; Hypertensive disorders of pregnancy
• ISSN: 2210-7789; 2210-7797
• DOI: 10.1016/j.preghy.2022.08.010

•There was no difference in PPR for HDP between 2012-13 and 2014-17.•IV magnesium administration for HDP with severe features remained below 80% across epochs.•Discharge prescriptions for antihypertensive drugs decreased for HDP with severe features. In response to 2013 guidelines for hypertensive disorders of pregnancy (HDP), our study examined changes in antenatal management and postpartum readmission (PPR) over time. This is a retrospective cohort study of individuals diagnosed antenatally with HDP who delivered at a tertiary care center from 2012 to 2017. The primary outcome was postpartum readmission for HDP in 2012-2013 vs. 2014-2017. Secondary outcomes included intravenous magnesium administration and prescription for oral (PO) antihypertensive medication during delivery admission. Multivariable logistic regression models assessed differences in outcomes over time, adjusted for age, race, and payer status, for HDP with and without severe features, defined by ACOG criteria. Of 5,300 eligible individuals, 73.5% had HDP without severe features and 26.5% had severe features. The PPR frequency in this cohort was 1.1% (N=59). There was no difference in PPR for individuals with HDP without severe features (aOR 0.73; 95% CI 0.28-1.88) or with severe features (aOR 1.30; 95% CI 0.50-3.39) by epoch. Magnesium administration for HDP with severe features remained below 80% over time. Magnesium administration for HDP without severe features and discharge prescriptions for PO medications for HDP with severe features were lower after 2013. Neither magnesium administration nor discharge prescriptions were associated with decreased odds of PPR. Although there was no difference in PPR for HDP after 2013, there were changes in antenatal management of HDP, including decreased magnesium administration for individuals with HDP without severe features and PO medication for individuals with severe features.